Tuesday, 02 January 2024 12:17 GMT

Cata-Kor Launches NMN Longevity Formula, Expanding Its NAD+ Line With An Advanced Cellular-Energy Solution


(MENAFN- Newsfile Corp) Cata-Kor Launches NMN Longevity Formula, Expanding Its NAD+ Line with an Advanced Cellular-Energy Solution

December 16, 2025 10:25 AM EST | Source: PRNews OU

Miami, Florida--(Newsfile Corp. - December 16, 2025) - Cata-Kor is introducing Cata-Kor NMN - Nicotinamide Mononucleotide Complex, a new product that expands the company's NAD+ portfolio in the Healthy Longevity category. The formula adds an additional biochemical route to supporting NAD+ levels and complements the brand's existing direct-form products, NAD+ Core (250 mg) and NAD+ Advanced (500 mg).




Cata-Kor NMN
To view an enhanced version of this graphic, please visit:

Cata-Kor has spent the past several years building a strong identity in the longevity space, focusing on cellular-energy pathways and science-based healthy-ageing formulations. The introduction of an NMN complex fits naturally into this direction, extending the NAD+ line with a complementary mechanism of action and giving consumers a broader set of longevity-oriented options.

This strategic direction is reflected in the biochemical distinctions within the line. Cata-Kor NMN is centred on Beta-Nicotinamide Mononucleotide (NMN), which supports cellular energy through a precursor-based pathway rather than direct NAD+ delivery. This distinction makes the NMN formula a complementary option to NAD+ Core and NAD+ Advanced, creating a clearer progression within the overall NAD+ portfolio.

The development of the formula took approximately two months. Each serving provides 500 mg of Beta-NMN combined with Resveratrol, Trimethylglycine (TMG) and Quercetin - ingredients commonly referenced in the context of metabolic processes, cellular maintenance and longevity-associated nutrition.

"Introducing NMN is a natural continuation of our NAD+ line," said Roman Miroedov, PhD, Product Development Lead at Cata-Kor. "We wanted to expand the category with a formula built around a different biochemical mechanism - one that reflects how the longevity field is evolving. The launch follows the strong performance of NAD+ Core and NAD+ Advanced, and it allows us to offer a more advanced option for those who already use NAD+ and are looking for the next step within the same scientific framework. Interest in NMN has grown worldwide, and both the market and our brand expertise in NAD+ support have matured enough for a dedicated NMN flagship."

The launch also reinforces Cata-Kor's positioning within the U.S. longevity segment. Over recent years, the brand has become closely associated with science-driven healthy-ageing solutions, and the NMN formula extends this identity by aligning with the company's longevity-focused portfolio through a complementary biochemical pathway.

Cata-Kor NMN - Nicotinamide Mononucleotide Complex became available in the United States on December 1, 2025. The product is not intended to diagnose, treat, cure or prevent any disease.

About Cata-Kor

Cata-Kor is a U.S.-based nutraceutical company developing longevity formulations to extend human lifespan. Reflecting the brand's long-term orientation toward longevity science, its portfolio is built around cellular energy mechanisms and healthy ageing pathways. Cata-Kor has a manufacturing facility in the United States and conducts all testing domestically, with a focus on transparency, quality and science-informed development.
Learn more at

Always consult a healthcare provider before starting any new dietary supplement.

Media Contact:
Roman Miroedov, PhD
...

To view the source version of this press release, please visit

Source: PRNews OU

MENAFN17122025004218003983ID1110489453



Newsfile Corp

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search